×
About 10,818 results

ALLMedicine™ Non-Hodgkin Lymphoma Center

Research & Reviews  3,427 results

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT04657224

Dec 3rd, 2021 - Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that plays a critical role in B cell activation via the B cell receptor (BCR) signaling pathway. BTK is important for normal B-cell activation and the pathophysiology of B cell malign...

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05008055

Dec 1st, 2021 - The study protocol follows a modular design. The study will investigate the safety and efficacy of capivasertib monotherapy in participants with R/R Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL).

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01695941

Dec 1st, 2021 - PRIMARY OBJECTIVES: I. To determine the recommended phase II dose of alisertib (MLN8237) and bortezomib when combined with rituximab in patients with relapsed/refractory mantle cell and B-cell low grade non-Hodgkin lymphoma. SECONDARY OBJECTIVES: ...

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic W...
https://doi.org/10.1182/bloodadvances.2021004926
Blood Advances; Tahri S, Mouhieddine TH et. al.

Dec 1st, 2021 - Clonal hematopoiesis (CH) is associated with adverse outcomes in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma undergoing autologous stem cell transplantation. Still, its implications for patients with indolent NHL have not been we...

Association between body composition and chemotherapy-related toxicity in children with...
https://doi.org/10.1002/cncr.34043
Cancer Wadhwa A, Adams KM et. al.

Dec 1st, 2021 - Body composition is associated with chemotherapy toxicity (chemotoxicity) in adults with cancer; this association remains unexplored in children with cancer. Using baseline computed tomography scans of 107 children with Hodgkin lymphoma (n = 45), ...

see more →

Guidelines  4 results

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Practical recommendations for fertility preservation in women by the FertiPROTEKT netwo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762797
Archives of Gynecology and Obstetrics; Schüring AN, Fehm T et. al.

Nov 28th, 2017 - Most guidelines about fertility preservation are predominantly focused on scientific evidence, but are less practically orientated. Therefore, practically oriented recommendations are needed to support the clinician in daily practice. A selective ...

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

see more →

Drugs  58 results see all →

Clinicaltrials.gov  153 results

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT04657224

Dec 3rd, 2021 - Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that plays a critical role in B cell activation via the B cell receptor (BCR) signaling pathway. BTK is important for normal B-cell activation and the pathophysiology of B cell malign...

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05008055

Dec 1st, 2021 - The study protocol follows a modular design. The study will investigate the safety and efficacy of capivasertib monotherapy in participants with R/R Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL).

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01695941

Dec 1st, 2021 - PRIMARY OBJECTIVES: I. To determine the recommended phase II dose of alisertib (MLN8237) and bortezomib when combined with rituximab in patients with relapsed/refractory mantle cell and B-cell low grade non-Hodgkin lymphoma. SECONDARY OBJECTIVES: ...

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphom...
https://clinicaltrials.gov/ct2/show/NCT04970901

Nov 29th, 2021 - This is a Phase 1b, multi-center, open-label, multi-arm study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polatuzumab vedotin, or umbralisib in participants with relapsed...

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Ped...
https://clinicaltrials.gov/ct2/show/NCT03526250

Nov 26th, 2021 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymph...

see more →

News  685 results

FDA Grants RMAT Designation to CTX110 for Relapsed/Refractory CD19+ B-Cell Malignancies
https://www.onclive.com/view/fda-grants-rmat-designation-to-ctx110-for-relapsed-refractory-cd19-b-cell-malignancies

Dec 1st, 2021 - The FDA has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to the allogeneic CAR T-cell therapy CTX110 for the treatment of patients with relapsed or refractory, CD19-positive B-cell malignancies, according to a news release f...

Dr. Stefanovic on the Emergence of Umbralisib in MZL and Follicular Lymphoma
https://www.onclive.com/view/dr-stefanovic-on-the-emergence-of-umbralisib-in-mzl-and-follicular-lymphoma

Nov 18th, 2021 - Alexandra Stefanovic, MD, associate professor of medicine, Department of Medicine, Duke University School of Medicine, hematologic oncologist, hematologist (malignant), Duke Cancer Center, Duke Health, discusses the emergence of umbralisib (Ukoniq...

Mortality Rate Associated With COVID-19 Breakthrough Cases Remains High in Hematologic Malignancies
https://www.onclive.com/view/mortality-rate-associated-with-covid-19-breakthrough-cases-remains-high-in-hematologic-malignancies

Nov 18th, 2021 - Although mortality rates in patients with hematologic cancers who develop breakthrough COVID-19 cases after vaccination are high, there has been a significant decrease in incidence since vaccines have become available, according to preliminary dat...

Younger Non-Hodgkin Lymphoma Survivors at Higher Risk for Age-Related Diseases
https://www.medscape.com/viewarticle/962285

Nov 8th, 2021 - NEW YORK (Reuters Health) - Younger survivors of B-cell non-Hodgkin's lymphoma (B-NHL) have a higher risk of developing acute renal failure, and possibly pneumonia and nutritional deficiencies, than their older peers, new research suggests. "Thank...

Research Project Aims to Make CAR-T-cell Therapy Safer and More Effective
https://www.onclive.com/view/research-project-aims-to-make-car-t-cell-therapy-safer-and-more-effective

Oct 11th, 2021 - A new project led by researchers at MUSC Hollings Cancer Center could significantly decrease the side effects associated with CAR-T-cell therapy and make the treatment available to more patients who could benefit. Led by Hollings hematologist and...

see more →